Literature DB >> 21053756

Heroin-dependent inmates' experiences with buprenorphine or methadone maintenance.

Ezechukwu Awgu1, Stephen Magura, Andrew Rosenblum.   

Abstract

Methadone and buprenorphine are both efficacious treatments for opioid dependency, but they also have different pharmacological properties and clinical delivery methods that can affect their acceptability to patients. This study was intended to increase our knowledge of heroin-dependent individuals' perceptions of methadone vs. buprenorphine maintenance based on actual experiences with each. The study sample consists of heroin-dependent men at the Rikers Island jail in New York City who were voluntarily randomly assigned to methadone or buprenorphine maintenance in jail. Methadone patients were more likely to report feeling uncomfortable the first few days, having side/withdrawal effects during treatment, and being concerned about continued dependency on medication after release. In contrast, buprenorphine patients' main issue was the bitter taste. All of the buprenorphine patients stated that they would recommend the medication to others, with almost all preferring it to methadone. Ninety-three percent of buprenorphine vs. 44% of methadone patients intended to enroll in those respective treatments after release, with an added one-quarter of the methadone patients intending to enroll in buprenorphine instead. These results reinforce the importance of increasing access to buprenorphine treatment in the community for indigent heroin-dependent offenders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21053756      PMCID: PMC3527632          DOI: 10.1080/02791072.2010.10400696

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  20 in total

1.  Beliefs about methadone in an inner-city methadone clinic.

Authors:  Sharon Stancliff; Julie Elana Myers; Stuart Steiner; Ernest Drucker
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Ambivalence toward methadone treatment among intravenous drug users.

Authors:  A Rosenblum; S Magura; H Joseph
Journal:  J Psychoactive Drugs       Date:  1991 Jan-Mar

3.  Buprenorphine: a controlled clinical trial in the treatment of opioid dependence.

Authors:  P P Pani; I Maremmani; R Pirastu; A Tagliamonte; G L Gessa
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

Review 4.  Misunderstandings about methadone.

Authors:  J E Zweben; J L Sorensen
Journal:  J Psychoactive Drugs       Date:  1988 Jul-Sep

5.  "It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment.

Authors:  D E Hunt; D S Lipton; D S Goldsmith; D L Strug; B Spunt
Journal:  Int J Addict       Date:  1985 Nov-Dec

6.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

7.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates.

Authors:  V Tomasino; A J Swanson; J Nolan; H I Shuman
Journal:  Mt Sinai J Med       Date:  2001-01

8.  Methadone maintenance: some client opinions.

Authors:  B S Brown; G J Benn; D R Jansen
Journal:  Am J Psychiatry       Date:  1975-06       Impact factor: 18.112

9.  Double-blind randomized trial of buprenorphine and methadone in opiate dependence.

Authors:  S Petitjean; R Stohler; J J Déglon; S Livoti; D Waldvogel; C Uehlinger; D Ladewig
Journal:  Drug Alcohol Depend       Date:  2001-03-01       Impact factor: 4.492

10.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.

Authors:  Richard P Mattick; Robert Ali; Jason M White; Susannah O'Brien; Seija Wolk; Cath Danz
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more
  24 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice.

Authors:  Johan Enquist; Madeline Ferwerda; Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-11-07       Impact factor: 4.030

3.  Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.

Authors:  Aaron D Fox; Adam Chamberlain; Taeko Frost; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2015       Impact factor: 3.716

4.  Predictors of outcome after short-term stabilization with buprenorphine.

Authors:  Maureen Hillhouse; Catherine P Canamar; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-09-26

5.  Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.

Authors:  Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham
Journal:  J Behav Health Serv Res       Date:  2017-07       Impact factor: 1.505

6.  Initiation of buprenorphine during incarceration and retention in treatment upon release.

Authors:  Nickolas Zaller; Michelle McKenzie; Peter D Friedmann; Traci C Green; Samuel McGowan; Josiah D Rich
Journal:  J Subst Abuse Treat       Date:  2013-03-27

7.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

8.  Extended-release naltrexone opioid treatment at jail reentry (XOR).

Authors:  Ryan D McDonald; Babak Tofighi; Eugene Laska; Keith Goldfeld; Wanda Bonilla; Mara Flannery; Nadina Santana-Correa; Christopher W Johnson; Neil Leibowitz; John Rotrosen; Marc N Gourevitch; Joshua D Lee
Journal:  Contemp Clin Trials       Date:  2016-05-10       Impact factor: 2.226

9.  I heard about it from a friend: assessing interest in buprenorphine treatment.

Authors:  Aaron D Fox; Pooja A Shah; Nancy L Sohler; Carolina M Lopez; Joanna L Starrels; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

10.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Andrew J Saxon; David Huang; Al Hasson; Christie Thomas; Maureen Hillhouse; Petra Jacobs; Cheryl Teruya; Paul McLaughlin; Katharina Wiest; Allan Cohen; Walter Ling
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.